Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

A legfontosabb adatok

Ki végzi
Christine Marx, MD
Hol
Durham (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
108 fő, tervezett
Kezdés
2024. szept. 6.
Várható befejezés
2027. aug. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Pregnenolone
  • Placebo
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
21 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • 21-65 years of age, any ethnic group, either sex
  • History of mild TBI since 2001 and service in the U.S. Military since 9/11/01 (OEF/OIF/OND era)
  • We will adhere to the operational definition of mild TBI suggested by the World Health Organization Task Force (Holm et al 2005), with the exception of Glasgow Coma Scale score criteria (not available for these participants): a.) 1 or more of the following: confusion or disorientation, loss of consciousness for 30 minutes or less, post-traumatic amnesia for less than 24 hours, and/or other transient neurological abnormalities such as focal signs, seizure, and intracranial lesion not requiring surgery; Glasgow Coma Scale (GCS) score of 13-15 after 30 minutes post-injury or later upon presentation for health care (GCS unavailable). This WHO diagnostic definition of mild TBI is also consistent with the CDC Report to Congress on Mild TBI in the United States, September 2003 (specifically, altered consciousness attributable to the head injury [=transient confusion, disorientation or impaired consciousness] or self-reported loss of consciousness lasting 30 minutes or less)
  • Ability to read/understand English and to participate fully in the informed consent process
  • No anticipated need to alter psychiatric or pain medications for duration of study involvement
  • No changes in psychotropic or behavioral interventions during the study or in the 2 weeks prior to study enrollment
  • Negative pregnancy test if female. Sexually active subjects are required to use a medically acceptable form of birth control if they are of childbearing potential and could become pregnant during the study

Ki nem vehet részt

  • Concomitant medications for co-occurring medical conditions are permissible for stable medical conditions that are reasonably well-controlled (for example, hypertension medications, statins, and oral hypoglycemic medications would generally be permissible if they appear to be effectively treating the underlying condition). Medications that could potentially confound study outcomes (for example, prednisone) are exclusionary
  • Exclusionary criteria will diverge slightly from the above WHO definition of mild TBI and exclude participants who report a history of seizures for this investigation
  • Participants who report a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the PI or in consultation with the participant's PCP/other health care provider)
  • Current DSM-5 diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than TBI
  • Known allergy to study medication
  • Substance use disorder (DSM-5), other than nicotine use disorder
  • Serious unstable medical illness. History of cerebrovascular accident, prostate, uterine or breast cancer. Medications to treat these conditions either acutely or chronically (for example, finasteride, tamoxifen, clopidogrel) are also exclusionary
  • Participants with current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern
  • Female participants who are pregnant or breast-feeding
  • Benzodiazepine or opioid use within the last 2 weeks is exclusionary
  • Use of oral contraceptives or other hormonal supplementation such as estrogen or progesterone, as there is a theoretical risk that a metabolite of pregnenolone could potentially impact efficacy of oral contraceptives and estrogen replacement

Helyszínek itt: Egyesült Államok

  • Duke University School of MedicineDurham, Egyesült Államok
  • Durham VA Health Care SystemDurham, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to compare pregnenolone and placebo (a placebo is a look-alike substance that contains no active drug) in Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND)-Era Veterans with a history of chronic Traumatic Brain Injury (TBI). The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

* Does pregnenolone improve psychological health, overall physical function, cognition, symptoms of PTSD, and pain more than placebo over the 8-week study period? * What are the biological effects of pregnenolone, and how do pregnenolone and other molecules change over the course of treatment? (and do pregnenolone and other molecules predict clinical improvement?)

Participants who are eligible and consent to participate in the study will:

* be randomized in a 1:1 ratio to take pregnenolone or placebo * be given pregnenolone or placebo to take each day at home * will participate in 6 visits over 11 weeks for tests, exams and procedures that are for study purposes (each visit will last 1.5 - 3 hours) * be evaluated at each visit to determine if there are any bad reactions to the study drug and if study participation is still appropriate * be financially compensated for their visit time and travel cost

A vizsgálat 2 csoportja

  • PregnenoloneMár használt kezelés, összehasonlításként
  • PlaceboPlacebo, összehasonlításként

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. november 12.